Japan approves world's first virus therapy for esophageal cancer

Japan has approved Telomelysin, a genetically modified adenovirus developed by Oncolys BioPharma, marking the world's first commercial therapy for esophageal cancer. The drug, also known as suratadenoturev or OBP-301, targets cancer cells by exploiting the high presence of telomerase enzyme in malignant cells, causing the virus to replicate extensively and destroy the cancer cell. Normal cells, which have low telomerase activity, are largely unaffected.

The development of Telomelysin began over 35 years ago with surgeon Toshiyoshi Fujiwara's research at Okayama University, exploring the potential of viruses as cancer weapons. The concept involved engineering an adenovirus to switch on its replication only when telomerase is present. This scientific breakthrough was later spun out into Oncolys BioPharma in 2004, co-founded by Fujiwara and pharmaceutical industry veteran Yasuo Urata.

Human trials commenced in the United States in 2006, with Phase I studies demonstrating the therapy's safety and some localized tumor shrinkage. However, regulatory hurdles and the conceptual challenge of introducing a self-replicating virus into the body presented significant obstacles. Researchers also discovered that Telomelysin could interfere with cancer cells' DNA repair mechanisms, enhancing its therapeutic potential, particularly when combined with treatments that damage DNA, such as radiation therapy.

The approval, granted on June 8, 2026, is for patients with esophageal cancer who are not eligible for standard curative resection or chemoradiotherapy. The therapy's development involved clinical trial results from 17 domestic facilities in Japan.